Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Iorio, L; Bond, M; Padoan, R; Dejaco, C.
Advances in the treatment of polymyalgia rheumatica.
Rheumatology (Oxford). 2025; 64(Supplement_1):i48-i54
Doi: 10.1093/rheumatology/keae539
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Dejaco Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Polymyalgia rheumatica (PMR) is a common inflammatory disorder affecting individuals over 50. The cornerstone of PMR treatment remains oral glucocorticoids (GCs), with initial doses tailored to the risk of relapse and comorbidities. However, relapses occur in up to 76% of cases, and long-term GC use is associated with significant toxicity, affecting up to 85% of patients. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate, offer limited benefits, while recent evidence supports the use of biologics, such as tocilizumab and sarilumab, in reducing GC dependency and achieving remission. Emerging treatments, including JAK inhibitors (tofacitinib) and B-cell depletion (rituximab), show promise but require further validation. The treat-to-target (T2T) strategy is advocated for achieving sustained remission and minimizing adverse effects. New treatment options requiring rheumatological expertise are emerging, highlighting the need for specialized management, early referral, improved imaging use, and standardized definitions of remission and relapse to enhance patient care and outcomes.
- Find related publications in this database (using NLM MeSH Indexing)
- Polymyalgia Rheumatica - drug therapy
- Humans - administration & dosage
- Glucocorticoids - therapeutic use
- Antirheumatic Agents - therapeutic use
- Remission Induction - administration & dosage
- Find related publications in this database (Keywords)
- polymyalgia rheumatica (PMR)
- GCA-PMR spectrum disease (GPSD)
- oral glucocorticoids (GCs)
- conventional DMARDs
- biologic DMARDs
- target DMARDs
- tocilizumab
- sarilumab
- rituximab
- JAK inhibitors